BiomX Inc. (PHGE) News

BiomX Inc. (PHGE): $0.50

0.01 (-1.81%)

POWR Rating

Component Grades

Momentum

NR

Stability

NR

Sentiment

Quality

NR

Add PHGE to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#NR of NR

in industry

Filter PHGE News Items

PHGE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest PHGE News From Around the Web

Below are the latest news stories about BIOMX INC that investors may wish to consider to help them evaluate PHGE as an investment opportunity.

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced it will host a virtual KOL Event on December 4, 2023 at 12:00 PM ET to discuss the positive topline results recently announced from Part 2 of Phase 1b/2a trial of BX004 in cystic fibrosis (CF) patients with chronic Pseudomonas

Yahoo | November 30, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a good way to start the day as we dive into the biggest news worth checking out on Wednesday morning!

William White on InvestorPlace | November 29, 2023

BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

BX004 showed clinically meaningful improvement in pulmonary function as measured in FEV11 and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain in a predefined subgroup of patients with reduced lung function2 Treatment with BX004 also achieved P. aeruginosa culture conversion to negative at end of 10 days of treatment in 3 patients (14%) versus none for placebo3 In a prespecified subgroup of patients on background use of continuous inhaled antibiotics, BX004 showed a 2.8 log10 CFU

Yahoo | November 29, 2023

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

Analysis of Part 2 data from Phase 1b/2a trial of BX004 ongoing; Company expects to announce Part 2 data later this month BX004 received FDA Fast Track designation in August Part 1 data recently presented at the North American Cystic Fibrosis Conference (NACFC) CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific p

Yahoo | November 14, 2023

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will present data from Part 1 of its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa (PsA) pulmonary infections in people with

Yahoo | October 27, 2023

BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Edward L. Williams to its Board of Directors. “We are pleased to welcome Eddie to our Board of Directors,” said Jonathan Solomon, Chief Executive Officer of BiomX Inc. “As a seasoned executive with extensive board experience

Yahoo | October 18, 2023

BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Company remains on track to report Part 2 results from the study in November 2023 Part 1 data of the Phase 1b/2a study accepted for oral presentation at upcoming IDWeek 2023 CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the completion of patient dosing in Part 2 of the Ph

Yahoo | October 4, 2023

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will present data from Part 1 of its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa (PsA) pulmonary infections in patients w

Yahoo | September 7, 2023

BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, which is being held virtually and in person on September 11-13, 2023, at Lotte New Y

Yahoo | September 6, 2023

BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update

Patient Screening Completed in Part 2 of Phase 1b/2a Trial of BX004 with patient enrollment expected to exceed original estimates FDA grants BX004 Fast Track designation Initial Data from Part 2 Now Expected in November 2023 Company Will Host a Conference Call and Webcast Today at 8:00 am ET CAMBRIDGE, Mass. and NESS ZIONA, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage t

Yahoo | August 9, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!